34 Phase 2 study of neoadjuvant docetaxel and androgen suppression (AS) Plus Radiation Therapy (RT) for high risk localized prostate cancer (HRLCaP) - McKenzie, M.; Chi, K.; Neville, A.; Ellard, S.; Baerg, B.; Ruether, D.; Winquist, E.; Segal, R.; Attwell, A.; Lukka, H. (Radiotherapy & Oncology, 2006)